The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update

The international, phase III, multi-centre AZA-001 trial demonstrated azacitidine (AZA) is the first treatment to significantly extend overall survival (OS) in higher risk myelodysplastic syndromes (MDS) patients (Fenaux (2007) Blood 110 817). The current treatment paradigm, which is based on a rela...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Silverman, LR, Fenaux, P, Mufti, GJ, Santini, V, Hellström-Lindberg, E, Gattermann, N, Sanz, G, List, AF, Gore, SD, Seymour, JF, Backstrom, J, McKenzie, D, Beach, CL
Natura: Artigo
Lingua:Inglês
Pubblicazione: Cancer Intelligence 2008
Soggetti:
Short Communications
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3234059/
https://ncbi.nlm.nih.gov/pubmed/22275990
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3332/ecancer.2008.118
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi